Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
118,165,642
-
Share change
-
+180,142
-
Total reported value
-
$3,408,098,233
-
Put/Call ratio
-
28%
-
Price per share
-
$28.84
-
Number of holders
-
261
-
Value change
-
-$32,772,311
-
Number of buys
-
130
-
Number of sells
-
131
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q3 2024
As of 30 Sep 2024,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
261 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
118,165,642 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, EcoR1 Capital, LLC, Avoro Capital Advisors LLC, VANGUARD GROUP INC, BlackRock, Inc., Deep Track Capital, LP, STATE STREET CORP, JPMORGAN CHASE & CO, MORGAN STANLEY, and BRAIDWELL LP.
This page lists
261
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.